Logan Coy Related postsA Multicenter, Randomized, Double-Blind, Adaptive Phase 2/3 Study of EIK1001 and Pembrolizumab vs Placebo and Pembrolizumab as First-Line Therapy in Advanced MelanomaSeptember 11, 2026A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaSeptember 11, 2026A Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after OsimertinibSeptember 11, 2026 Previous postA Phase 2, Randomized, Open-label Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic SyndromeNext postA Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to Ruxolitinib